Argenx to Buy Forte Biosciences for $2.2 Billion
Argenx has announced a $2.2 billion acquisition of Forte Biosciences, marking a significant expansion of its immunology pipeline.
The story so far
Argenx is set to acquire Forte Biosciences, Inc. for $2.2 billion. The deal incorporates Forte’s first-in-class anti-CD122 antibody, FB102, into the Argenx immunology portfolio.
Coverage from outlets including the Wall Street Journal, STAT, Axios, and Fierce Biotech highlights the strategic focus on autoimmune assets, specifically noting FB102's current phase 2 stage of development for vitiligo. Market analysis regarding the transition is underway, as Investing.com reports that TD Cowen has downgraded its rating of Forte Biosciences stock following the announcement of the acquisition.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.
Sources (10)
- argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline Yahoo Finance · 1d ago
- Argenx to buy autoimmune-focused Forte Biosciences for $2.2B STAT · 1d ago
- argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline GlobeNewswire · 1d ago
- TD Cowen downgrades Forte Biosciences stock rating on Argenx deal Investing.com · 1d ago
- Argenx to acquire Forte Biosciences for $2.2B Axios · 1d ago
- TD Cowen downgrades Forte Biosciences stock rating on Argenx deal By Investing.com Investing.com Canada · 1d ago
- argenx to buy Forte Bio for $2.2B in immunology push FirstWord Pharma · 1d ago
- Argenx to pick up autoimmune biotech Forte Biosciences for $2.2B Endpoints News · 1d ago
- Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug Fierce Biotech · 1d ago
- Argenx to Buy Forte Biosciences for $2.2 Billion WSJ · 1d ago
The obvious questions
What is the primary asset included in the deal?
The acquisition includes FB102, a first-in-class anti-CD122 antibody.
What is the total value of the acquisition?
The agreement is valued at $2.2 billion.
Has the market responded to the news?
Yes, TD Cowen downgraded its stock rating for Forte Biosciences following the announcement.
How fast it spread
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Topics
Related trends
MapLight shares sink on mixed ph. 2 schizophrenia readout
MapLight Therapeutics stock has declined following mixed topline results from the Phase 2 ZEPHYR trial of its schizophrenia candidate, ML-007C-MA.
Brown-Forman turns down ‘unsolicited’ Sazerac offer
Brown-Forman has formally rejected an unsolicited $15 billion takeover bid from rival spirits company Sazerac.
FDA staff flags data concerns about Capricor's therapy; shares plunge
Capricor Therapeutics faces market volatility and legal investigations following the release of FDA staff documents regarding its therapy, Deramiocel.
United reportedly approached Delta Air Lines about a potential merger
Reports indicate United Airlines CEO Scott Kirby approached Delta Air Lines regarding a potential merger.
Paramount Agrees to Delay Warner Bros. Merger for Months
Paramount has agreed to pause its acquisition of Warner Bros. Discovery as legal challenges against the merger move through the court system.
Precise DNA base editing using AlphaFold3-based contact modelling
Researchers are utilizing AlphaFold3-based contact modelling to redesign gene-editing proteins, aiming to improve safety in CRISPR applications.